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Barrier-to-autointegration factorVaccinia-related kinase 3 (VRK3) is known as a pseudokinase that is catalytically inactive due to changes in
motifs that are essential for kinase activity. Although VRK3 has been regarded as a genuine pseudokinase from
structural and biochemical studies, recent reports suggest that VRK3 acts as an active kinase aswell as a signaling
scaffold in cells. Here, we demonstrate that VRK3 phosphorylates the nuclear envelope protein barrier-to-
autointegration factor (BAF) on Ser4. Interestingly, VRK3 kinase activity is dependent upon its N-terminal
regulatory region, which is excluded from the determination of its crystal structure. Furthermore, the kinase
activity of VRK3 is involved in the regulation of the cell cycle. VRK3 expression levels increase during interphase,
whereas VRK1 is enriched in late G2 and early M phase. Ectopic expression of VRK3 induces the translocation of
BAF from the nucleus to the cytoplasm. In addition, depletion of VRK3 decreases the population of proliferating
cells. These data suggest that VRK3-mediated phosphorylation of BAF may facilitate DNA replication or gene
expression by facilitating the dissociation of nuclear envelope proteins and chromatin during interphase.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Protein kinases are key regulators of most cellular processes, includ-
ing metabolism, transcription, cell cycle progression, apoptosis, and
differentiation [14]. Protein kinase superfamilies comprise approxi-
mately 2–3% of human genes [23] and are designated as the ‘kinome.’
Unexpectedly, nearly 10% of the human kinome have been categorized
as pseudokinases on the basis of a lack of one or more of the conserved
amino acids required for kinase activity. Therefore, pseudokinases are
predicted to be enzymatically inactive [3]. Although approximately
10% of protein kinases are predicted to be catalytically inactive
pseudokinases, recent biochemical and structural studies have revealed
that several of them are enzymatically active, suggesting that atypical
mechanisms of protein phosphorylation are at work in the cell [6,7,27,
38–40].
Vaccinia-related kinase 3 (VRK3) is a member of mammalian
vaccinia-related kinases (VRKs), a novel family of mammalian serine/
threonine protein kinases that was initially characterized by its homol-
ogy to the vaccinia virus B1R kinase [28]. Recent studies identiﬁed the
essential roles of the VRK family in cell signaling, nuclear envelope
dynamics, histone modiﬁcation, apoptosis, and cell stress responses
[18,21,30,32]. Our previous studies demonstrated that VRK3 negatively
regulatesMAP kinase signaling by promoting the activity of the vaccinia
H1-related (VHR) phosphatase, which speciﬁcally dephosphorylatesiosciences and Biotechnology,
ong, San 31, Pohang 790-784,
99.and inactivates extracellular signal-regulated kinases (ERKs) in the
nucleus [16,17]. It is noteworthy that VRK3 elevates the phosphatase
activity of VHR by a mechanism independent of its kinase activity [16].
Sequence analyses predict that VRK3 has mutations in three conserved
amino acids in the catalytic domain that is required for kinase activity [3,
23]. VRK3 reportedly cannot incorporate 32P into casein in contrast to
other VRK family members and casein kinases [28]. In addition, the
structure of the VRK3 catalytic domain was revealed to be incapable of
binding ATP [34]. These data collectively support the notion that VRK3
is a ‘dead’ protein kinase. Thus, VRK3 is currently classiﬁed as a truly
inactive pseudokinase [42]. However, the kinase activity of full-length
VRK3, which retains the extracatalytic domain, has not been rigorously
examined, especially under physiological conditions. In our previous
report, VRK3 showed putative kinase activity in a cellular context [16].
Moreover, it was suggested that VRK3 functions as an active protein
kinase like VRK1 and VRK2 while this work was in an initial stage
[37]. Therefore, it is unclear whether VRK3 has an unconventional
mode of kinase action, like some other active pseudokinases [7].
Barrier-to-autointegration factor (BAF) is an essential nuclear enve-
lope protein that links the nuclear envelope and chromatin [24,35]. BAF
is localized in the nucleus and is highly enriched in the nuclear envelope
[26]. Phosphorylation and dephosphorylation of BAF are required for
disassembly and reassembly, respectively, of the nuclear envelope
during mitosis [1,9]. It is well known that mitotic phosphorylation of
BAF at its N-terminus by VRK1 strongly reduces the afﬁnity of BAF for
chromatin and LEM proteins, thus contributing to nuclear envelope
breakdown during early mitosis [10,25,28,29]. Notably, the levels of
mitotic VRK1 are enriched from late G2 to prophase, and its residual
activity is suppressed by histone variant macroH2A1.2 in the nucleus
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is phosphorylated during interphase, the kinase responsible for this
reaction and its role remains elusive [2].
Even though VRK3 has been regarded as an inactive pseudokinase
from sequence and structural analyses, we demonstrate that VRK3
functions as an active protein kinase on BAF, which is dependent upon
its N-terminal extracatalytic domain. We also present the possibility
that VRK3-mediated BAF phosphorylation is associated with cell cycle
progression during interphase.
2. Results
2.1. VRK3 interacts with the nuclear envelope protein BAF in cells
Although the kinase domain of VRK3 was demonstrated to be
inactive in a study of its protein structure [34], the data presented in
our previous study suggest that the kinase activity of full-length recom-
binant VRK3 protein is retainedwhen it is preincubatedwithwhole-cell
lysates [16]. Thus, we hypothesized that the kinase activity of VRK3may
bedependent upon co-regulators or substrates. To systemically discover
the cellular binding partners that are required for VRK3 kinase activity,
FLAG-tagged human VRK3was transfected into HEK 293A cells, follow-
ed by co-immunoprecipitation with anti-FLAG antibodies. LTQ-orbitrap
mass spectrometric analysis was then performed to identify VRK3-
interacting proteins [13]. We identiﬁed that the nuclear envelope
protein BAF was associated with VRK3 in this proteomic analysis (data
not shown).
To validate the interaction between VRK3 and BAF, HEK 293A
cells were transfected with constructs encoding FLAG-tagged VRK3,
and co-immunoprecipitation assays were performed. As a result, ec-
topically expressed VRK3 formed a complex with endogenous BAF
(Fig. 1A) in accordance with mass spectrometric data. In addition,
endogenous VRK3 was also co-immunoprecipitated with FLAG-
tagged BAF (Fig. 1B).
To conﬁrm the interaction between VRK3 and BAF at endogenous
protein levels, HEK 293A cell lysates were prepared and endogenous
VRK3 immunoprecipitationwas performed using anti-VRK3 antibodies.
We found that BAF was co-immunoprecipitated with endogenously
expressed VRK3 in HEK 293A cells (Fig. 1C). Furthermore, results of
immunoﬂuorescence experiments show that FLAG-tagged VRK3 co-
localized with endogenous BAF in the same subcellular compartment
of HEK 293A cells. As shown in Fig. 1D, VRK3, which has a nuclear local-
ization signal, and BAF were both prominently present in the nucleus
[11]. In addition, a nuclear envelop marker Lamin B is also colocalized
with VRK3 in the nucleus (Fig. 1E). These results suggest that nuclear-
localized VRK3 associates with nuclear envelope protein BAF in HEK
293A cells.
2.2. VRK3 phosphorylates BAF on Ser4 in vitro
Although recombinant VRK3 failed to phosphorylate casein in vitro
[28], the kinase activity of VRK3 has not been rigorously tested using
authentic binding partners. Thus, we examined whether VRK3 phos-
phorylates BAF in the presence of various divalent cations. We used
puriﬁed GST-VRK3 for an in vitro kinase assay, which showed phos-
phorylation of histidine-tagged BAF (His BAF) when either Mg2+ or
Mn2+ was used as a divalent cation for the kinase reaction (Fig. 2A).
However, autophosphorylation of recombinant VRK3 was not detected
in this assay using radiolabeled ATP (Fig. 2B). To further conﬁrm the
VRK3 kinase activity, we used other substrates, such as casein and
histone H3, in an in vitro kinase assay. As a result, VRK3 only phosphor-
ylated BAF, but not casein or histone H3 (Fig. 2B). In contrast, VRK1
robustly phosphorylated BAF, including casein and histone H3 (Supple-
mentary Fig. 1). These data suggest that VRK3 has a distinct mode of
action different from that of VRK1 and other casein kinase family
members.To validate the BAF phosphorylation mediated by VRK3, we con-
structed BAF mutants, in which the N-terminal serine or threonine
residues were substituted with alanine. BAF is phosphorylated on
Thr2, Thr3, and Ser4 by VRK1 in a cell cycle-speciﬁc manner [2,3].
According to in vitro kinase assay results, the initial phosphorylation
of Ser4 induced the subsequent phosphorylation of Thr2 and Thr3.
Thus, Ser4 is regarded as a primary VRK1 phosphorylation site [29].
Therefore, we needed to assess whether N-terminal residues are also
phosphorylated by VRK3. Notably, the catalytic ability of VRK3 to phos-
phorylate BAF was completely abrogated when the Ser4 residue was
mutated to alanine (Fig. 2C). This result implies that VRK3 also plays a
role as a BAF kinase in cells.
As we previously reported, the mutation of Lys182 abolishes the
putative autophosphorylation of mouse VRK3 after preincubation with
an HT22 cell lysate [16]. This residue of mouse VRK3 is equivalent to
Lys203 of human VRK3. Thus, we subsequently tested whether the
kinase activity of VRK3 was abrogated when Lys203 is mutated to
glutamic acid (K203E). In vitro kinase assay results showed that the
VRK3 K203E mutant failed to catalyze the phosphorylation reaction of
BAF, suggesting that the K203E mutant is inactive (Fig. 2D).
To analyze the catalytic activity of VRK3 in cells, VRK3 immunopre-
cipitates were incubated with exogenous recombinant BAF. As expect-
ed, phosphorylation of wild-type BAF was also detected in an in vitro
kinase assay using FLAG-tagged VRK3, whereas phosphorylation of
mutant BAF Ser4A was not detected (Fig. 2E). Collectively, these data
suggest that VRK3 is an active protein kinase that phosphorylates BAF
in vitro and in vivo.
2.3. N-terminal region of VRK3 is required for its kinase activity
Even though a substantial fraction of all presumed pseudokinases
turn out to be catalytically active, VRK3 is regarded as a genuinely inac-
tive pseudokinase, because a structural study showed that it is incapable
of binding ATP [23,34,42]. In this study, however, we presented VRK3 as
an active BAF kinase. Themost notable difference between the previous
structural study and our biochemical assay is that the N-terminally
truncated, catalytic domain of VRK3 (residues 148–472) was used to
elucidate its crystal structure [34], whereas the full-length form of
VRK3 (VRK3 FL) was employed to test its kinase activity. Therefore,
we constructed a catalytic domain of VRK3 that is devoid of N-
terminal residues, designated VRK3 (ΔN1–147). This construct encom-
passes the entire catalytic domain of VRK3 used in the previous
structural study.
Initially, we compared the kinase activities of VRK3 FL and VRK3
(ΔN1–147) towards BAF in vitro. As shown in Fig. 3A, VRK3 FL
phosphorylated BAF in a concentration-dependent manner, consistent
with previous observations. In contrast, VRK3 (ΔN1–147) was unable
to phosphorylate BAF, indicating that the N-terminal region (residues
1–147) is required for VRK3 activity in vitro. Additionally, FLAG-
tagged VRK3 (ΔN1–147) immunoprecipitates failed to incorporate
radiolabeled ATP into BAF (Fig. 3B). Furthermore, FLAG-tagged VRK3
(ΔN1-147) was unable to form a complex with endogenous BAF in a
co-immunoprecipitation assay (Fig. 3C). Actually, VRK3 (ΔN1–147)
was localized to the cytosol in cells (Supplementary Fig. 2). In addition,
just the N-terminal region of VRK3 (N1-147) is not sufﬁcient to interact
with BAF (Supplementary Fig. 4). Taken together, both N-terminal
extracatalytic domain and kinase domain of VRK3 appear to be required
for proper conformation to interact and phosphorylate BAF.
2.4. BAF phosphorylation mediated by VRK3modulates its association with
nuclear components
BAF interacts with LEM domain-containing proteins, such as LAP2,
emerin, and Man1, in the inner nuclear membrane, [24] contributing
to the integrity of the nuclear envelope. It was reported that ectopic
expression of VRK1 and BAF lessened the association of BAF with the
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Fig. 1. VRK3 speciﬁcally interacts with BAF in cells. (A) Whole-cell lysates from HEK293A cells transfected with pFLAG (Mock) or pFLAG-VRK3were immunoprecipitated with anti-FLAG
antibodies, and the precipitates as well as input sample were immunoblottedwith antibodies to FLAG, BAF, or GAPDH. (B)Whole-cell lysates fromHEK293A cells transfectedwith pFLAG
(Mock) or pFLAG-BAF were immunoprecipitated with anti-FLAG antibodies, and the precipitates and input sample were immunoblotted with antibodies to FLAG, VRK3, or GAPDH.
(C)Whole-cell lysates collected fromHEK293A cells were used for endogenous immunoprecipitationwith anti-VRK3 antibodies. The VRK3 immunoprecipitates were analyzed by immu-
noblotting with antibodies to VRK3 or BAF. (D) HEK293A cells were transfected with pFLAG-VRK3. Nuclei were stained with Hoechst, and the localization of BAF and VRK3was observed
with ﬂuorescence microscopy. (E) HEK293A cells were transfected with pFLAG-VRK3. Nuclei were stained with Hoechst, and the localization of Lamin B and VRK3 was observed with
ﬂuorescence microscopy. The scale bars in panels D and E represent 10 μm. All immunoblotting results are from at least three separate experiments.
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cytosol [29]. Thus, we assessedwhether VRK3 kinase activity can trigger
the redistribution of BAF in cells. First, ectopically expressed EGFP-BAF
maintained its nuclear localization in A549 cells. However, when
FLAG-tagged VRK3 and EGFP-BAF were co-transfected into A549 cells,there was a substantial increase in the cytoplasmic localization of
EGFP-BAF (Fig. 4A and C, Supplementary Fig. 5). In contrast, the catalyt-
ically inactive VRK3 K203Emutant could not substantially alter the sub-
cellular localization of EGFP-BAF. Furthermore, the VRK3-dependent
translocation of BAFwas diminishedwhen its Ser4 residuewasmutated
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Fig. 2. Identiﬁcation of VRK3 kinase activity in vitro. (A) A VRK3 kinase assay was performed using recombinant GST-VRK3(2 μg)in the presence of various divalent cations. His-tagged
BAF(1 μg) was used as a substrate. (B) A VRK3 kinase assay was performed using recombinant GST-VRK3 (2 μg) in the presence of various substrates. His-tagged BAF (1 μg), casein
(1 μg) and histone H3 (1 μg) were used as substrates. (C) Identiﬁcation of BAF residues phosphorylated by VRK3. Recombinant His-BAF (WT, 1 μg) or the His-BAF S4A mutant (1 μg)
was incubated with GST-mouse VRK3 (GST-mVRK3. 2 μg) or GST- human VRK3 (GST-hVRK3, 2 μg). (D) GST-VRK3 (WT, 2 μg) or GST-VRK3 (K203E, 2 μg) was incubated with His-
BAF(1 μg) as a substrate. (E) HEK293A cells were transfected with pFLAG-VRK3. After 24 h, whole-cell lysates were immunoprecipitated with anti-FLAG antibodies. In vitro immune
complex kinase assays were performed without exogenous protein, or with His-BAF(1 μg) or His-BAF S4A(1 μg) as substrates.
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LEM protein emerin, which interacts with BAF.
2.5. Cell cycle-dependent expression of VRK3
VRK1 is known to phosphorylate BAF on Ser4, Thr2, and Thr3 to
promote mitotic nuclear envelope disassembly [1,9,10]. Our studies
show that VRK3 also catalyzes the phosphorylation of the Ser4 residue
of BAF. Thus, both VRK1 and VRK3 are able to phosphorylate the Ser4
residue of BAF. Therefore, we wished to delineate the roles of VRK3 in
cell cycle regulation compared to VRK1. To do this, we ﬁrst examined
the levels of VRK3 in HeLa cells at different stages of the cell cycle
(Fig. 5A). As we previously reported, the protein levels of VRK1 were
enriched when mitotic arrest was induced by treatment with
nocodazole [18]. In contrast, VRK3 levels increased in the G1 phase,
after cell cycle arrest induced by hydroxyurea. Some cell cycle markers
such as cyclin B, cyclin E and phospho-Rb also suggest that the expres-
sion of VRK3 is enriched in interphase (Fig. 5A) The cell cycle-
dependent accumulation of VRK3 was seen in A549 cells, consistent
with results observed in HeLa cells, suggesting that enrichment ofVRK3 during interphase is not conﬁned to a speciﬁc cell line (Fig. 5B).
In addition, HeLa cells were synchronized at the G1/S boundary using
the double thymidine blockmethod. As shown in Fig. 4C, at the indicat-
ed time points of release, the VRK3protein gradually decreased, indicat-
ing that VRK3 is differentially expressed during cell cycle progression
and peaks during the G1/S phase (Fig. 5C).
To further evaluate the role of VRK3 in cell cycle progression, we
identiﬁed the S-phase cell populations. The portion of BrdU-positive
cells increased when HeLa cells were transfected with wild-type
VRK3, but not with the kinase-inactive K203E mutant (Fig. 5D). The
involvement of VRK3 in cell cycle progression was also examined
by reducing VRK3 levels using shRNA (Fig. 5G). Flow cytometric
analyses revealed that the population of BrdU-positive cells de-
creased after VRK3 knockdown (Fig. 5E and F). In addition, when
we tested growth of mouse embryonic ﬁbroblast (MEF) isolated
from VRK3 depleted mice VRK3−/− MEFs grew noticeably slower
than wild-type control (Fig. 5H). Collectively, these results suggest
that the expression of VRK3 may be associated with BAF phosphory-
lation during interphase, which promotes cell cycle progression,
especially in the G1/S phase.
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Fig. 3. N-terminus dependent phosphorylation of BAF by VRK3. (A) Comparison of kinase activity of full-length VRK3 and truncated VRK3(Δ1–147). GST-VRK3 full length (FL) or GST-
VRK3 (Δ1–147) was incubated with His-BAF(1 μg) as a substrate. (B) HEK293A cells were transfected with pFLAG, pFLAG-VRK3, and pFLAG-VRK3(Δ1–147) respectively. After 24 h,
whole-cell lysates were immunoprecipitatedwith anti-FLAG antibodies. In vitro immune complex kinase assayswere performedwith His-BAF(1 μg) as a substrate. (C)Whole-cell lysates
from HEK293A cells transfected with pFLAG (Mock), pFLAG-VRK1, pFLAG-VRK3, or pFLAG-VRK3(Δ1–147) were immunoprecipitatedwith anti-FLAG antibodies, and the precipitates and
input sample were immunoblotted with antibodies to FLAG or BAF.
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3.1. The N-terminal regulatory region is essential for VRK3 kinase activity
As previously mentioned, a considerable fraction of presumed
pseudokinases turn out to be catalytically active, suggesting that nonca-
nonical mechanisms of phosphorylation exist in cells [7]. One of the
most remarkable examples of active pseudokinase is the Ca2+/Fig. 4. Ectopic expression of VRK3 induces BAF translocation. (A) A549 cells were transfectedw
After 24 h, cells were ﬁxed and stained with anti-FLAG antibodies. The localization of BAF and
plasmids encoding EGFP-BAF S4A, with or without pFLAG-VRK3 WT. After 24 h, cells were ﬁxe
with ﬂuorescence microscopy. (C) The percentage of cytoplasmic GFP positive cells are calcula
as the mean ± SD of four independent experiments. At least 100 hundreds cells are counted at
with Hoechst, and the localization of emerin and VRK3 was observed with ﬂuorescence microscalmodulin-dependent serine/threonine kinase (CASK) [19,27]. Unlike
conventional protein kinases, CASK functions in the absence of divalent
cations. Intriguingly, its activity is suppressed by Mg2+. Another exam-
ple is Her3 (human epidermal growth receptor 3), the pseudokinase
counterpart of EGFR, which shows mild autophosphorylation activity
when it is clustered in reconstituted vesicles [36]. Actually, Her3 has
no kinase activity under standard conditions without vesicles [38]. Ad-
ditionally, KSR (kinase suppressor of ras) provides a remarkableith plasmids encoding EGFP-BAF, with orwithout pFLAG-VRK3WT or pFLAG-VRK3 K203E.
VRK3 was observed with ﬂuorescence microscopy. (B) A549 cells were transfected with
d and stained with anti-FLAG antibodies. The localization of BAF and VRK3 was observed
ted among co-transfected cells with FLAG-VRK3 and EGFP-BAF. The results are expressed
each experiment. (D) A549 cells were transfected with pFLAG-VRK3. Nuclei were stained
copy. The scale bars in panels A, B and D represent 10 μm.
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found that the pseudokinase domains of both KSR1 and KSR2 possess
kinase activity through an allosteric mechanism [4]. Taken together,
these ﬁndings clearly demonstrate that several pseudokinases are
catalytically active in a context-dependent manner using novel mecha-
nisms. Therefore, it is conceivable that other presumed pseudokinases
may also be active protein kinases with atypical reaction mechanisms.
In this study, we show that VRK3 functions as an active BAF ki-
nase; this activity is dependent on the N-terminal region (N1–147)
of VRK3. According to the secondary structure of the proteinpredicted by its amino acid sequence, the N-terminal extracatalytic
domain of VRK3 lacks a stable secondary structure and is expected
to be highly ﬂexible (Supplementary Fig. 3). This region may hinder
the successful crystallization of full-length VRK3 protein. This might
explain why the N-terminus of VRK3 was deleted in the elucidation
of its protein structure. However, this region of VRK3 has multiple
targets for Pro-directed S/T kinases, such as cyclin-dependent ki-
nases and mitogen-activated protein kinases [8]. In fact, the N-
terminus of VRK3 was shown to be highly phosphorylated in several
phosphoproteomic studies [5,12,15,41,43], suggesting that this
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1745C.-H. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1738–1748region may have a regulatory role for its catalytic activity. According
to previous structural studies, the ATP-binding pocket of the VRK3
catalytic domain (ΔN1–147) is blocked by large hydrophobic side
chains. For catalytic activity, this pocket must be accessible [22,34].
Thus, we hypothesize that the N-terminal regulatory region of
VRK3 contributes to the opening of the closed ATP-binding pocket
for its kinase activity. It will be very interesting to determine the
entire structure of VRK3, including the N-terminal region. We thus
anticipate that unraveling the full structure of VRK3 may reveal
another atypical kinase mechanism.3.2. Role of VRK3 in cell cycle regulation
BAF interactswith various nuclear envelope proteins, and its binding
properties are tightly regulated in a cell cycle-dependent manner [1,11,
24,35]. As reported, the localization of BAF ﬂuctuates during the
cell cycle [11]. In early mitosis, BAF is released from the nuclear
envelope and is evenly dispersed throughout the cytoplasm.
Hyperphosphorylation of BAF on Thr2, Thr3, and Ser4 by VRK1 initiates
the disassembly of the complex containing LEM proteins, chromatin,
and BAF [10,29]. At the end of mitosis, protein phosphatases such as
Interphase
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Fig. 6. Hypothetical model. Differential roles of VRK3 and VRK1 in cell cycle regulation.
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reassemble with LEM proteins and chromatin at the end of mitosis [9].
As is well known, BAF is robustly phosphorylated on Ser4 by VRK1
during mitosis, yet it is also phosphorylated on Ser4 during interphase
[29]. It is not clear why BAF is phosphorylated in interphase as well as
in mitosis. One possibility is that BAFmust be released from the nuclear
envelope and chromatin to facilitate DNA replication. Another possibil-
ity is that the interaction of BAF and LEM proteinsmust beweakened to
regulate gene expression associated with emerin and lamin during
interphase [2]. In this study, we show that the level of VRK3 is enriched
in the G1 phase. Moreover, the overexpression of VRK3 increases the
population of proliferating cells,whereas knockdownof VRK3 decreases
the population of proliferating cells. These data imply that VRK3 is
involved in cell cycle progression during interphase by diminishing
the association between BAF and chromatin. In addition, ectopically
expressed VRK3 causes the relocalization of nuclear BAF, indicating
that VRK3-mediated BAF phosphorylation also releases LEM proteins
and subsequently regulates LEM-associated gene expression during
interphase.
Collectively, these data suggest that VRK3 mediates BAF hypo-
phosphorylation on Ser4 during interphase, thus promoting DNA repli-
cation and regulating gene expression. We thus propose a hypothetical
model presenting differential roles for VRK1 and VRK3 in cell cycle
regulation (Fig. 6). Duringmitosis, BAF hyperphosphorylationmediated
by VRK1 causes nuclear envelope breakdown required for the progres-
sion of mitosis. However, during interphase, BAF hypophosphorylation
mediated by VRK3 induces the disassociation of BAF, LEM proteins,
and chromatin, thereby contributing to the DNA replication and related
gene expression during interphase.
4. Materials and methods
4.1. Antibodies and reagents
Hydroxyurea, thymidine and nocodazole were purchased from
Sigma (St. Louis, MO). [γ-32P]ATP was from NEN Life Science Products
(Boston, MA). The rabbit polyclonal antibody against BAF was a gift
from Dr. Tokuko Haraguchi (Advanced ICT Research Institute Kobe,
Japan). The rabbit polyclonal anti-phospho-BAF antibody was a gift
from Dr. Robert Craigie (National Institute of Health, Bethesda, MD).Anti-VRK3 (HPA-016040) and anti-FLAG antibody (clone M2) were
from Sigma (St. Louis, MO); anti-Lamin B (C-20, SC-6216), anti-
emerin (FL-254, SC-15378) and anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, 0411, SC-47724) were from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-cyclin B (#4158), anti-cyclin E
(#4129), anti-Rb (#9313) and anti-phospho-Rb (#8516) were from
Cell Signaling Technology (Danvers, MA); anti-histone H3 (phosphor
S10, ab5176) was from Abcam (Cambridge, UK). Antibodies are diluted
to 0.2 μg/ml for immunoblotting or 2 μg/ml for immunocytochemical
analysis.
4.2. Plasmid construction
Human full-length VRK3was ampliﬁed by PCR fromHeLa cell cDNA.
For mammalian expression constructs, VRK3 coding region was cloned
into pFLAG-CMV (Sigma) vector. Kinase-dead mutant (Lys 203 to Glu)
was generated by site-directed mutagenesis and subcloned into
pFLAG-CMV (Sigma) vector.
4.3. Preparation of recombinant VRK3 and BAF proteins
Complete VRK3 coding region and the deletion mutant (△N1–147)
were cloned into pGEX-4T-3 (Pharmacia Biotech, Uppsala, Sweden).
The resulting plasmids were transformed into Escherichia coli
BL21(DE3) to produce GST tag-VRK3 fusion proteins after treating
with 0.1 M isopropyl-1-thio-β-D-galactopyranoside for 24 h at 18 °C.
Bacteria were lysed in a phosphate-buffered saline (PBS) containing
1 mM dithiothreitol, 1 mM PMSF, and 1 mM Na3VO4. The GST fusion
proteins were then puriﬁed using glutathione-sepharose resin
(Amersham Biosciences, Little Chalfont, UK) and eluted from the
beadswith reduced glutathione according to themanufacturer's recom-
mendations. The mutant constructs were conﬁrmed by DNA se-
quencing. Complete BAF coding region is cloned into pProEx HTa
(Invitrogen, Carlsbad. CA). His BAF protein was prepared from the
insoluble fraction of bacterial cell lysates. BAF containing pellet was
extracted under denaturing conditions using guanidine buffer (6 M
guanidine-HCl, 150 mM KCl, 20 mM HEPES, pH 7.6, 2 mM β-
mercaptoethanol, 0.1 mM EDTA, 5 mM imidazole). After centrifugation
to remove any remaining insoluble material, the supernatant is mixed
1747C.-H. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1738–1748with Ni-NTA Agarose bead (Invitrogen, Carlsbad. CA). 6× His-tagged
BAF protein was puriﬁed according to manufacturer's instructions.
4.4. VRK3 in vitro kinase assay
The kinase assaywas carried out in a total volume of 30 μl of a kinase
reaction buffer containing 50 μM ATP, and afﬁnity-puriﬁed GST fusion
proteins or 500 μg/ml His-BAF as a substrate for 2 h incubation at
37 °C. The phosphorylated proteins were resolved on 15% Tricine–
SDS–polyacrylamide gels [33].
4.5. Cell culture and transfection
HEK293A, HeLa and A549 cells were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) containing 10% fetal bovine serum
and antibiotics in a humidiﬁed 5% CO2 incubator at 37 °C. HEK293A
cells were transfected with the plasmid indicated in the speciﬁc
experiments by using Lipofectamine 2000 (Invitrogen). After incuba-
tion for 24 h, the transfected cells were treated as indicated for analysis.
The pLL 3.7 LentiLox system (Addgene, Cambridge, MA) was used to
generate shRNA. The shRNA sequence targeting VRK3 are 5′-ACTCAA
GGCCTGCTGTTTA-3′.
4.6. Immunoblotting and immunoprecipitation
Immunoblotting analysis was performed aswe previously described
[30,31]. For immunoprecipitation, cell lysates were prepared in lysis
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerol phosphate, 10 μg/ml pepstatin A, 10 μg/ml leupeptin, 1 mM
PMSF, 10 μg/ml aprotinin, 10 mM NaF, and 1 mM Na3VO4). Equal
amounts of proteins were immunoprecipitated using anti-VRK3 or
anti-FLAG antibodies and collected with protein G-Sepharose beads
(GE healthcare) at 4 °C for 16 h. The immunoprecipitate was then
washed four times in cold lysis buffer and subjected to Western blot
analysis and VRK3 kinase assay.
4.7. Immunocytochemical analysis
Cells were grown on coated glass coverslips. For immunocytochem-
istry, cells were ﬁxed with 4% PFA and then incubated with blocking
solution (2.5% bovine serum albumin and 2.5% equine serum in PBS)
for 1 h at room temperature. The samples were incubated overnight
at 4 °C with anti-VRK3 antibody (Sigma), followed by incubation
with Alexa546-conjugated anti-rabbit IgG. Slides were mounted and
visualized by ﬂuorescence microscopy (Axioplan2, Zeiss; Oberkochen,
Germany).
4.8. Cell cycle synchronization and ﬂow cytometry
HeLa cells were synchronized in G1 by treatment for 24 hwith 2mM
hydroxyurea, A double thymidine blocking was performed by treating
cells 2 mM thymidine for 20 h, released for 6 h in fresh DMEM contain-
ing 10% FBS, and treated again with 2 mM thymidine for 12 h. Cells
arrested in G1/S were released by switching the medium to fresh
DMEM containing 10% FBS. For ﬂow cytometric analysis, the cells
were ﬁxed with 70% ethanol for 20 min, stained with 20 μg/ml
propidium iodide, and treated with 1 μg/ml RNase A for 10 min at
room temperature. Samples containing 10,000 cells were then analyzed
on a FACSCalibur system (Becton Dickinson).
4.9. Isolation of VRK3−/−MEFs
VRK3 knockout mice are generated using genetrap ES cell line
(YTA189, http//genetrap.org).Wild type and VRK3−/−mouse embryonicﬁbroblasts (MEFs) were isolated from 12.5 days of embryos. MEFs at
passage 2 (p2) were used for growth curves.
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